# Drug Reform Group Proposes Options to Address High-THC Marijuana Risks > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/high-thc-cannabis-policy-options-address-risks/ > **Published:** 2026-04-06T15:03:40-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:29:28-04:00 > **Clinical Summary:** Explore high-thc cannabis policy options to reduce risks without criminalization, focusing on regulation and harm reduction strategies. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic High-Potency CannabisThcPsychosis RiskCannabis PolicyHarm Reduction Why This Matters High-THC cannabis products increasingly dominate legal markets, with concentrates often exceeding 70-90% THC compared to traditional flower’s 15-25%. This concentration shift has clinical implications for psychosis risk, tolerance development, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), particularly in vulnerable populations including adolescents and those with psychiatric predispositions. Clinical Summary Drug policy reform advocates are exploring regulatory approaches to address concentrated THC products without reverting to criminalization. Options likely include potency caps, taxation structures based on THC content, enhanced labeling requirements, and age-based restrictions. The clinical concern centers on emerging evidence linking high-potency cannabis to increased rates of psychotic episodes and cannabis hyperemesis syndrome, though causation versus correlation remains debated. Current legal markets often lack meaningful potency regulation despite these emerging safety signals. Dr. Caplan’s Take “We’re essentially conducting a massive uncontrolled experiment with high-potency cannabis products. While I don’t advocate returning to prohibition, the clinical reality is that 90% THC concentrates present different risk profiles than traditional cannabis flower—and our regulatory frameworks haven’t caught up to the pharmacology.” Clinical Perspective 🧠 Clinicians should screen for specific product types and potencies when assessing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), not just frequency. Patients using concentrates or high-THC products may require different counseling about psychosis risk and tolerance. Watch for regulatory changes that could affect product availability and patient access patterns. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Drug%20Reform%20Group%20Lays%20Out%20Options%20To%20Address%20High-THC%20Marijuana%27s%20Risks%20Without...%20%40drcaplan&url=https%3A//www.marijuanamoment.net/drug-reform-group-lays-out-options-to-address-high-thc-marijuanas-risks-without-returning-to-criminalization/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marijuanamoment.net/drug-reform-group-lays-out-options-to-address-high-thc-marijuanas-risks-without-returning-to-criminalization/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Drug%20Reform%20Group%20Lays%20Out%20Options%20To%20Address%20High-THC%20Marijuana%27s%20Risks%20Without...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marijuanamoment.net/drug-reform-group-lays-out-options-to-address-high-thc-marijuanas-risks-without-returning-to-criminalization/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/drug-reform-group-lays-out-options-to-address-high-thc-marijuanas-risks-without-returning-to-criminalization/](https://www.marijuanamoment.net/drug-reform-group-lays-out-options-to-address-high-thc-marijuanas-risks-without-returning-to-criminalization/) Table of Contents - [FAQ](#FAQ)[What is high-potency cannabis?](#What_is_high-potency_cannabis) - [How does high-potency cannabis increase psychosis risk?](#How_does_high-potency_cannabis_increase_psychosis_risk) - [Who is most at risk from high-potency cannabis use?](#Who_is_most_at_risk_from_high-potency_cannabis_use) - [What are the clinical implications for healthcare providers?](#What_are_the_clinical_implications_for_healthcare_providers) - [How might this research influence cannabis policy?](#How_might_this_research_influence_cannabis_policy) - [Related](#Related) ## FAQ #### What is high-potency cannabis? High-potency cannabis refers to marijuana products with elevated levels of THC (tetrahydrocannabinol), the psychoactive compound responsible for cannabis’s intoxicating effects. These products typically contain significantly higher THC concentrations than traditional cannabis strains. #### How does high-potency cannabis increase psychosis risk? Higher THC concentrations can disrupt brain function and trigger psychotic episodes, particularly in vulnerable individuals. The risk is especially pronounced in young people whose brains are still developing and those with a predisposition to mental health conditions. #### Who is most at risk from high-potency cannabis use? Adolescents and young adults face the highest risk due to ongoing brain development. Individuals with a family history of psychosis, schizophrenia, or other [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/) are also particularly vulnerable to adverse effects. #### What are the clinical implications for healthcare providers? Healthcare providers should screen patients for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns and educate them about potency-related risks. Early identification and intervention are crucial for preventing long-term mental health consequences, particularly in high-risk populations. #### How might this research influence cannabis policy? These findings may prompt policymakers to consider regulations on THC potency limits and enhanced labeling requirements. The research supports the need for evidence-based cannabis policies that prioritize public health and safety while informing consumer choices. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [High-potency cannabis linked to mental health risks, expert warns](https://cedclinic.com/high-potency-cannabis-linked-to-mental-health-risks-expert-warns/) An expert discusses the mental health risks associated with high-potency cannabis and the implications for users and policymakers. [Read More](https://cedclinic.com/high-potency-cannabis-linked-to-mental-health-risks-expert-warns/) [High-Potency Cannabis: America's New Pastime and Psychiatry's Next Challenge](https://cedclinic.com/high-potency-thc-products-psychiatry-challenges/) This article explores the rise of high-potency cannabis use and its emerging challenges for psychiatric care and public health. [Explore Article](https://cedclinic.com/high-potency-thc-products-psychiatry-challenges/) [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) A detailed look at cannabinoids and their therapeutic roles, providing context for understanding cannabis potency and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Learn More](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).